MacTel is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

The U.S. Food and Drug Administration (FDA) has announced significant advancements in medical treatments, including the ...

The first treatment for macular telangiectasia type 2 is set to enter the market following U.S. FDA approval of NT-501 ...

Opens in a new tab or window The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia (MacTel) type 2, Neurotech Pharmaceuticals ...

for the treatment of Macular Telangiectasia type 2 (MacTel). MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly ...

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular ...

About Macular Telangiectasia Type 2 (MacTel) Macular Telangiectasia Type 2 (MacTel), or idiopathic macular telangiectasia type 2, is a bilateral, neurodegenerative disease in adults with ...